Participants in the study will be randomly assigned to receive either cabozantinib plus supportive care or just supportive care. The study will monitor the participants over a period to see how the treatment affects the progression of the disease. The trial will also assess the safety of cabozantinib and how the body processes the drug, which is known as pharmacokinetics. The study will involve regular check-ups and assessments to track the health and progress of the participants.

The trial aims to provide valuable information on whether cabozantinib can help improve the outcomes for young people with osteosarcoma. The study will last for several months, and participants will be closely monitored throughout the process to ensure their safety and to gather data on the effectiveness of the treatment. The results of this study could potentially lead to better treatment options for those affected by this challenging condition.

Participants will be assigned to receive either mifamurtide, which is administered through intravenous use (delivered directly into a vein), or a standard treatment containing sorafenib, which is taken as an oral use medication. The study will monitor how well the treatments work over time and track any side effects that may occur during the course of the therapy.

The main goal of this research is to understand the long-term safety of GD2IL18CART treatment. The study will follow patients who have already received this treatment to monitor how they respond over time. During the study, doctors will track any delayed side effects that might occur, including the possibility of infections, cancer returning, or new health problems developing.

The study involves regular check-ups to monitor patients’ health status. For younger patients, growth and development will also be monitored. The research team will collect information about the patients’ overall health and perform tests to check if the treatment cells are still present in their bodies. This long-term monitoring will help understand how the treatment affects patients over time.

The purpose of the study is to determine the safety and appropriate dosage of GD2IL18CART and to see how well it works in treating these cancers. Participants will receive the treatment through an intravenous infusion, which means it will be delivered directly into the bloodstream. The study will monitor participants for any side effects and measure how the cancer responds to the treatment over time. Some participants may receive a placebo, which is a substance with no active treatment, to compare the effects of the new therapy.

Throughout the study, researchers will carefully observe the participants’ health and the behavior of the cancer. The study aims to find the best dose of GD2IL18CART that is both safe and effective. Participants will be followed for a period to assess the treatment’s impact on their cancer and overall health. This trial is an important step in developing new therapies for cancers that are difficult to treat with existing methods.

The study combines two types of treatment: a medication called trabectedin (given through an intravenous infusion) and low-dose radiation therapy. Trabectedin is administered as a solution that is prepared from a powder and given through a special tube placed in a vein. The dose used in this study is 1.5 milligrams per square meter of body surface.

The main goal of this research is to determine how well tumors respond to this combination treatment, particularly in areas that receive radiation therapy. Throughout the study, researchers will monitor changes in tumor size, track how long the treatment remains effective, and assess its effects on pain levels and overall well-being. They will also carefully watch for any side effects that may occur during treatment.

The purpose of the study is to determine if adding mifamurtide to the usual chemotherapy regimen can improve the outcomes for patients with high-risk osteosarcoma. Participants in the study will receive either the standard chemotherapy alone or the standard chemotherapy combined with mifamurtide. The treatment will be administered over a period of several weeks, and the effects will be monitored to see if the combination helps in preventing the cancer from returning or spreading.

Throughout the study, participants will be closely observed to track their progress and any side effects they may experience. The study aims to provide valuable information on whether the addition of mifamurtide can enhance the effectiveness of chemotherapy in treating high-risk osteosarcoma, potentially leading to better survival rates and outcomes for patients. The trial will continue until the estimated end date in 2033, allowing researchers to gather comprehensive data on the long-term effects and benefits of the treatment.

The purpose of this study is to see how well these medications work together in stopping the progression of these sarcomas over a period of six months. Participants in the study will receive pembrolizumab as an infusion, which means it is given directly into the bloodstream through a vein, and cabozantinib as a tablet taken by mouth. The study will last for up to 24 months, during which time the participants will be monitored regularly to assess the effects of the treatment on their cancer.

Throughout the study, doctors will use imaging techniques like MRI or CT scans to check the size of the tumors and see if they are responding to the treatment. The study aims to determine if the combination of pembrolizumab and cabozantinib can help control the disease and improve the quality of life for patients with these advanced sarcomas. Participants will also be monitored for any side effects from the medications to ensure their safety during the trial.

The study will be conducted in two parts. In the first part, participants with advanced solid tumors will receive the combination of cobolimab and dostarlimab to assess safety and determine the appropriate dosage. In the second part, the study will focus on specific types of cancer, including melanoma and Hodgkin lymphoma, to evaluate the effectiveness of the treatment. Participants will receive the medications through an intravenous infusion, which means the medicine is given directly into a vein.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The trial will help researchers gather important information about the potential benefits and risks of using cobolimab and dostarlimab together in treating these challenging conditions. The study is expected to continue until 2030, providing valuable insights into new treatment options for young patients with difficult-to-treat tumors.

Participants in the study will receive either the GnRHa treatment or a placebo, which is a substance with no active medication. The GnRHa treatment being studied is called Pamorelin, which is given as an injection. There are two different doses of Pamorelin being used in the study: 3.75 mg and 11.25 mg. The study will follow participants for several years to monitor their ovarian reserve and other health factors. This includes measuring levels of a hormone called Anti-Müllerian Hormone (AMH), which helps indicate the number of eggs left in the ovaries, at various points after the end of chemotherapy.

Throughout the study, participants will have regular check-ups to assess their ovarian reserve and overall health. This will involve tests like ultrasounds and blood tests to measure hormone levels. The study aims to provide valuable information on how GnRHa might help preserve fertility in young women and teenagers undergoing cancer treatment. By understanding the effects of this treatment, researchers hope to improve future care for patients facing similar challenges.